Back to top
more

AC Immune (ACIU)

(Delayed Data from NSDQ)

$3.91 USD

3.91
218,113

0.00 (0.00%)

Updated Jul 26, 2024 04:00 PM ET

Pre-Market: $3.99 +0.08 (2.05%) 9:00 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Top Ranked Momentum Stocks to Buy for January 30th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 30th.

Kinjel Shah headshot

5 Biotech Stocks Set to Beat Q3 Earnings Estimates

Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.

Linde (LIN) to Report Q3 Earnings: What's in the Cards?

Favorable industrial production in the United States is likely to have favored Linde's (LIN) Q3 earnings.

AC Immune (ACIU) Expected to Beat Earnings Estimates: Should You Buy?

AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AC Immune to Earn Milestone From Lilly for Alzheimer's Drug

AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.

Kinjel Shah headshot

6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day

Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.

Analysts Estimate AC Immune (ACIU) to Report a Decline in Earnings: What to Look Out for

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AC Immune Initiates Phase I Study for Alzheimer's Disease

AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.

AC Immune (ACIU) Lags Q1 Earnings and Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of -36.09% and -29.52%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

AC Immune (ACIU) to Report Q1 Results: Wall Street Expects Earnings Growth

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003

Alector, Inc. (ALEC) initiates the phase I INTERCEPT study on AL003 for the treatment of Alzheimer???s disease.

Lilly (LLY) Signs New Immunology Deal With Private Biotech

Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.

What Makes AC Immune (ACIU) a New Buy Stock

AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings?

Bio-Rad (BIO) apprehends a year-over-year decline in revenues within Life Sciences segment due to difficult comparison.

Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings?

An increased reimbursement of approximately $1 million has boosted Amedisys' (AMED) Hospice business.

What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings?

Strong domestic sales along with the launch of the t:slim X2 Insulin Pump in select international markets are likely to drive Tandem Diabetes' (TNDM) Q4 earnings.

What Makes AC Immune (ACIU) a New Buy Stock

AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AC Immune Enters Oversold Territory

AC Immune SA (ACIU) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Roche Halts Two Late-Stage Studies on Alzheimer's Candidate

Roche (RHHBY) discontinues two phase III studies evaluating its anti-beta-amyloid molecule, crenezumab in people with early sporadic Alzheimer's disease.

Top Ranked Momentum Stocks to Buy for January 25th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 25th:

Top Ranked Momentum Stocks to Buy for January 23rd

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 23rd:

Top Ranked Momentum Stocks to Buy for January 22nd

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 22nd:

Moving Average Crossover Alert: AC Immune

AC Immune SA (ACIU) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Stemline Therapeutics (STML) in Focus: Stock Moves 9.5% Higher

Stemline Therapeutics (STML) shares rose nearly 10% in the last trading session, amid huge volumes.

Biogen Inks Two Deals to Make Drugs for Neurological Diseases

Biogen (BIIB) signs deals with C4 Therapeutics and Skyhawk Therapeutics to develop potential therapies for Alzheimer's disease (AD), Parkinson's disease and other neurological diseases.